Since studies with NSCLC xenograft models indicated that BTZ pharmacokinetics and tumor penetration were limiting factors determining its efficacy [81], strategies to enhance BTZ efficacy focused on combination therapies, improving tumor penetration and second-generation PIs. The gene discussed is CASC3; the disease is non-small cell lung carcinoma.